Patient-reported outcomes in the phase 3 BFORE trial of bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Cancer Research and Clinical Oncology"
DOI: 10.1007/s00432-019-02894-3
Abstract: BackgroundIn the phase 3 BFORE trial (NCT02130557), treatment with bosutinib resulted in a significantly higher major molecular response rate at 12 months versus imatinib in the modified intent-to-treat (mITT) population of patients with newly diagnosed chronic… read more here.
Keywords: phase; newly diagnosed; treatment; bfore trial ... See more keywords
Tyrosine kinase inhibitor (TKI) therapy for newly-diagnosed patients with chronic myeloid leukemia: focusing on TKI discontinuation due to adverse events – is better always good?
Sign Up to like & getrecommendations! Published in 2017 at "Expert Review of Hematology"
DOI: 10.1080/17474086.2017.1339599
Abstract: The management of patients with chronic myeloid leukemia (CML) has changed dramatically with the introduction of imatinib. Although many patients with CML in chronic phase (CML-CP) achieve and maintain durable responses under imatinib, some need… read more here.
Keywords: trial; newly diagnosed; myeloid leukemia; bosutinib ... See more keywords
Application of Physiologically Based Pharmacokinetic Modeling in Understanding Bosutinib Drug-Drug Interactions: Importance of Intestinal P-Glycoprotein
Sign Up to like & getrecommendations! Published in 2018 at "Drug Metabolism and Disposition"
DOI: 10.1124/dmd.118.080424
Abstract: Bosutinib is an orally available Src/Abl tyrosine kinase inhibitor indicated for the treatment of patients with Ph+ chronic myelogenous leukemia at a clinically recommended dose of 500 mg once daily. Clinical results indicated that increases… read more here.
Keywords: physiologically based; drug; bosutinib; pbpk model ... See more keywords
Impact of Diarrhea on Health-Related Quality of Life: Analysis of the Phase 3 BFORE Trial of Bosutinib Vs Imatinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
Sign Up to like & getrecommendations! Published in 2018 at "Blood"
DOI: 10.1182/blood-2018-99-110152
Abstract: Introduction: In the ongoing phase 3 BFORE trial (NCT02130557), a significantly higher major molecular response rate at Month 12 was seen with bosutinib vs imatinib in patients with newly diagnosed chronic phase chronic myeloid leukemia… read more here.
Keywords: treatment; chronic diarrhea; bosutinib; fact ... See more keywords
Efficacy and Safety Following Dose Reduction of Bosutinib or Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia: Analysis of the Phase 3 BFORE Trial
Sign Up to like & getrecommendations! Published in 2018 at "Blood"
DOI: 10.1182/blood-2018-99-110543
Abstract: Introduction: Bosutinib, an oral dual Src/Abl tyrosine kinase inhibitor (TKI) is approved for patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML), at a starting dose of 400 once daily (QD) in newly diagnosed patients… read more here.
Keywords: reduction; bosutinib; research funding; consultancy ... See more keywords
Pregnancy Outcomes in Patients Treated with Bosutinib
Sign Up to like & getrecommendations! Published in 2018 at "Blood"
DOI: 10.1182/blood-2018-99-110547
Abstract: Introduction: Studies in animals have shown reproductive toxicity with bosutinib exposure, with teratogenic events in maternal exposure, but little is known about its effect during conception or pregnancy in humans. Methods: Here we describe pregnancy… read more here.
Keywords: bosutinib; pregnancy; consultancy; research funding ... See more keywords
Bosutinib prevents vascular leakage by reducing focal adhesion turnover and reinforcing junctional integrity.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of cell science"
DOI: 10.1242/jcs.240077
Abstract: AIMS Endothelial barrier dysfunction leads to edema and vascular leak, carrying high morbidity and mortality. Previously, Abl kinase inhibition was shown to protect against vascular leak. Using the distinct inhibitory profiles of clinically available Abl… read more here.
Keywords: turnover; endothelial barrier; bosutinib; vascular leakage ... See more keywords
Abrogation of transforming growth factor-β-induced tissue fibrosis in TBRIcaCol1a2Cre transgenic mice by the second generation tyrosine kinase inhibitor SKI-606 (Bosutinib)
Sign Up to like & getrecommendations! Published in 2018 at "PLoS ONE"
DOI: 10.1371/journal.pone.0196559
Abstract: Transforming growth factor-β (TGF-β) plays a crucial role in the pathogenesis of Systemic Sclerosis (SSc) and other fibrotic disorders. TGF-β-mediated c-Abl and Src kinase activation induces strong profibrotic cascade signaling. The purpose of this study… read more here.
Keywords: bosutinib; kinase inhibitor; fibrosis; tissue fibrosis ... See more keywords
Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase I/II study
Sign Up to like & getrecommendations! Published in 2018 at "Haematologica"
DOI: 10.3324/haematol.2017.171249
Abstract: Bosutinib is a Src/Abl tyrosine kinase inhibitor indicated for adults with newly-diagnosed Philadelphia positive chronic myeloid leukemia or with resistant/intolerant disease. We report the final results of a phase I/II study of second-line bosutinib in… read more here.
Keywords: phase; myeloid leukemia; year; bosutinib ... See more keywords